<DOC>
	<DOCNO>NCT00820911</DOCNO>
	<brief_summary>This study ass safety efficacy AEB071 combine everolimus CNI-free ( calcineurin inhibitor ) regimen renal transplant recipient .</brief_summary>
	<brief_title>Efficacy Safety AEB071 Versus Cyclosporine de Novo Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Inclusion criterion : Patient maintain study drug 12 month core study Exclusion criterion : Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kidney transplant</keyword>
	<keyword>AEB071</keyword>
</DOC>